2020年美国食品药品监督管理局潮汐计划（肽与寡核苷酸）成果
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest.
作者信息
Al Musaimi Othman, Al Shaer Danah, Albericio Fernando, de la Torre Beatriz G
机构信息
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
出版信息
Pharmaceuticals (Basel). 2021 Feb 11;14(2):145. doi: 10.3390/ph14020145.
2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
由于2019冠状病毒病（COVID-19）大流行，2020年是极其艰难且充满挑战的一年，这一年大部分精力都投入到应对全球健康危机上。美国食品药品监督管理局（FDA）已批准了53种新的药物实体，其中6种属于肽类和寡核苷酸类（TIDES）药物。这类药物的获批数量与前几年相似，这反映出TIDES市场的巩固。在此，对2020年获批的TIDES药物从化学结构、医学靶点、作用方式和不良反应等方面进行分析。
Zotero 插件